肿瘤细胞治疗研究
英文原题：Characterization of ex vivo expanded natural killer cells for cancer immunotherapy.
我们的研究结果表明，来自供体外周血单个核细胞的NK细胞能够稳定扩增，并对血液肿瘤和实体瘤均展现出强效的抗癌效果及ADCC作用，突显了其作为肿瘤学中一种多用途治疗方法的潜力。
在本研究中，我们采用共培养系统从健康供者和乳腺癌患者中体外扩增自然杀伤（NK）细胞，并研究其表面标志物表达。我们进一步使用细胞因子阵列和降维技术分析了第13天原代扩增NK细胞的活化标志物。在第0天、第6天和第13天（TS-NK）观察细胞因子谱。为验证扩增NK细胞的抗癌活性，我们使用来自10名供者（5名癌症患者和5名健康个体）的细胞，针对血液系统肿瘤细胞系K562进行了乳酸脱氢酶实验。此外，我们检测了分化NK细胞在HER2靶向单克隆抗体曲妥珠单抗和帕妥珠单抗存在下与SK-BR-3细胞共培养时的抗体依赖性细胞介导的细胞毒性（ADCC）。我们的研究结果表明，NK细胞可从供者外周血单个核细胞中稳定扩增，并对血液系统肿瘤和实体瘤均具有强效抗癌作用和ADCC，突显了其作为肿瘤学中多功能治疗方法的潜力。
In this study, we employed a coculture system to expand natural killer (NK) cells ex vivo from healthy donors and patients with breast cancer and investigated their surface marker expression. We further analyzed the activation markers of primary expanded NK cells on Day 13 using cytokine arrays and dimensionality reduction techniques. Cytokine profiles were observed on Days 0, 6 and 13 (TS-NK). To validate the anticancer activity of the expanded NK cells, we conducted lactate dehydrogenase assays against the hematologic cancer cell line K562 using cells from 10 donors (five patients with cancer and five healthy individuals). Additionally, we examined the antibody-dependent cellular cytotoxicity (ADCC) of differentiated NK cells cocultured with SK-BR-3 cells in the presence of the HER2-targeting monoclonal antibodies, trastuzumab and pertuzumab. Our findings demonstrate the stable expansion of NK cells from donor peripheral blood mononuclear cells and their potent anticancer effects and ADCC against both hematologic and solid tumors, highlighting their potential as a versatile therapeutic approach in oncology.
MEMBER ACCOUNT
登录成功会直接打开下一页。
